<p>Kestra Medical Technologies, Ltd.（納斯達克股票代碼：KMTS - 獲取免費報告）的股票在目前覆蓋該公司的五家評級機構中獲得了 “持有” 的共識評級，Marketbeat 報道稱。一位投資分析師給予該股票賣出評級，一位給予持有評級，三位給予買入評級。在過去一年中，更新了對該股票覆蓋的分析師的平均一年目標價為 27.40 美元。</p>
<p>多家券商對 KMTS 進行了評論。高盛集團在 4 月 9 日的報告中將 Kestra Medical Technologies 的目標價從 22.00 美元下調至 17.00 美元，並對該股票設定了 “中性” 評級。BTIG Research 在 4 月 7 日的報告中重申了對 Kestra Medical Technologies 的 “買入” 評級，並設定了 32.00 美元的目標價。最後，Weiss Ratings 在 3 月 23 日的報告中重申了對 Kestra Medical Technologies 的 “賣出（d-）” 評級。</p>
<p><strong>閲讀我們關於 KMTS 的最新股票報告</strong></p>
<h2>Kestra Medical Technologies 的內部買賣情況</h2>
<p>在其他新聞中，內部人士 Brian Daniel Webster 於 4 月 15 日星期三出售了該公司 15,000 股股票。該股票以平均價格 20.04 美元出售，總交易額為 300,600.00 美元。出售完成後，該內部人士直接持有該公司 349,786 股股票，估值約為 7,009,711.44 美元。這代表其持股比例下降了 4.11%。該交易已在向美國證券交易委員會（SEC）提交的法律文件中披露，相關文件可通過此超鏈接訪問。在過去的九十天裏，內部人士出售了價值 988,650 美元的 45,000 股公司股票。公司內部人士持有該公司股票的 3.60%。</p>
<h2>Kestra Medical Technologies 的機構交易情況</h2>
<p>機構投資者最近調整了對該股票的持有情況。Mirae Asset Global Investments Co. Ltd. 在第三季度購買了價值 562,000 美元的 Kestra Medical Technologies 新股份。Jennison Associates LLC 在第四季度將其在 Kestra Medical Technologies 的持股比例提高了 15.0%。Jennison Associates LLC 現在擁有 219,355 股該公司的股票，估值為 5,817,000 美元，此前在此期間又購買了 28,573 股。TD Asset Management Inc 在第三季度將其在 Kestra Medical Technologies 的持股比例提高了 17.3%。TD Asset Management Inc 現在擁有 92,306 股該公司的股票，估值為 2,193,000 美元，此前在此期間又購買了 13,588 股。China Universal Asset Management Co. Ltd. 在第三季度購買了價值 48,000 美元的 Kestra Medical Technologies 新股份。最後，Russell Investments Group Ltd. 在第四季度將其在 Kestra Medical Technologies 的持股比例提高了 43.5%。Russell Investments Group Ltd. 現在擁有 1,563 股該公司的股票，價值 41,000 美元，此前在上個季度又購買了 474 股。</p>
<h2>Kestra Medical Technologies 股票表現</h2>
<p>納斯達克 KMTS 的股票在星期二開盤價為 20.55 美元。該公司的債務與股本比率為 0.15，流動比率為 7.32，速動比率為 7.32。該股票的 50 日移動平均價格為 21.34 美元，200 日移動平均價格為 24.20 美元。Kestra Medical Technologies 的一年低點為 13.25 美元，一年高點為 30.00 美元。該公司的市值為 12 億美元，市盈率為-5.19，貝塔值為 0.82。</p>
<p>Kestra Medical Technologies（納斯達克股票代碼：KMTS - 獲取免費報告）最近於 3 月 17 日星期二發佈了季度財報。該公司報告季度每股收益（EPS）為（0.61）美元，低於分析師的共識預期（0.60）美元，差額為（0.01）美元。Kestra Medical Technologies 的淨利潤率為-171.87%，股本回報率為-65.49%。該公司在本季度的收入為 2455 萬美元。與去年同期相比，該公司的季度收入增長了 62.7%。分析師平均預測，Kestra Medical Technologies 在當前年度將發佈-2.34 美元的每股收益。</p>
<h2>關於 Kestra Medical Technologies</h2>
<p>（獲取免費報告）</p>
<p>我們是一家商業階段的可穿戴醫療設備和數字醫療公司，專注於通過直觀、智能和互聯的監測和治療干預技術來改善心血管疾病患者的結果。我們開發並商業化了我們的心臟恢復系統平台，這是一個綜合且先進的系統，將監測、治療、數字健康和患者支持服務整合為一個統一的解決方案。我們心臟恢復系統平台的基石是 ASSURE WCD，這是一種下一代可穿戴心臟復律除顫器（“WCD”），用於保護面臨突發心臟驟停（“SCA”）風險的患者，這是一項重大公共衞生問題，約佔美國所有心血管死亡的 50%。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，超過 Kestra Medical Technologies</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S01UUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S01UUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Kestra Medical Technologies 嗎？</h2>
<p>在考慮投資 Kestra Medical Technologies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Kestra Medical Technologies 並不在名單上。</p>
<p>雖然 Kestra Medical Technologies 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

KMTS

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

<p>Kestra Medical Technologies, Ltd.（納斯達克代碼：KMTS）獲得了五家券商的 “持有” 共識評級。分析師們給出了一個賣出、一個持有和三個買入評級，平均目標價為 27.40 美元。高盛將其目標價從 22.00 美元下調至 17.00 美元，而 BTIG Research 維持買入評級，目標價為 32.00 美元。內部人士 Brian Daniel Webster 出售了 15,000 股，減少了 4.11% 的持股比例。該股票開盤價為 20.55 美元，市值為 12 億美元，上一季度的每股收益為負 0.61 美元</p>

<p>Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have received a consensus rating of &#34;Hold&#34; from the five ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $27.40.</p>
<div class="lb-trans"><p>Kestra Medical Technologies, Ltd.（納斯達克股票代碼：KMTS - 獲取免費報告）的股票在目前覆蓋該公司的五家評級機構中獲得了 “持有” 的共識評級，Marketbeat 報道稱。一位投資分析師給予該股票賣出評級，一位給予持有評級，三位給予買入評級。在過去一年中，更新了對該股票覆蓋的分析師的平均一年目標價為 27.40 美元。</p>
</div><p>A number of brokerages have commented on KMTS. The Goldman Sachs Group decreased their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a &#34;neutral&#34; rating on the stock in a report on Thursday, April 9th. BTIG Research reaffirmed a &#34;buy&#34; rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd.</p>
<div class="lb-trans"><p>多家券商對 KMTS 進行了評論。高盛集團在 4 月 9 日的報告中將 Kestra Medical Technologies 的目標價從 22.00 美元下調至 17.00 美元，並對該股票設定了 “中性” 評級。BTIG Research 在 4 月 7 日的報告中重申了對 Kestra Medical Technologies 的 “買入” 評級，並設定了 32.00 美元的目標價。最後，Weiss Ratings 在 3 月 23 日的報告中重申了對 Kestra Medical Technologies 的 “賣出（d-）” 評級。</p>
</div><p><strong>Read Our Latest Stock Report on KMTS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 KMTS 的最新股票報告</strong></p>
</div><h2>Insider Buying and Selling at Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 的內部買賣情況</h2>
</div><p>In other news, insider Brian Daniel Webster sold 15,000 shares of the company's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $20.04, for a total transaction of $300,600.00. Following the completion of the sale, the insider directly owned 349,786 shares in the company, valued at approximately $7,009,711.44. This represents a 4.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 45,000 shares of company stock worth $988,650. Corporate insiders own 3.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Brian Daniel Webster 於 4 月 15 日星期三出售了該公司 15,000 股股票。該股票以平均價格 20.04 美元出售，總交易額為 300,600.00 美元。出售完成後，該內部人士直接持有該公司 349,786 股股票，估值約為 7,009,711.44 美元。這代表其持股比例下降了 4.11%。該交易已在向美國證券交易委員會（SEC）提交的法律文件中披露，相關文件可通過此超鏈接訪問。在過去的九十天裏，內部人士出售了價值 988,650 美元的 45,000 股公司股票。公司內部人士持有該公司股票的 3.60%。</p>
</div><h2>Institutional Trading of Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 的機構交易情況</h2>
</div><p>Institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Kestra Medical Technologies during the 3rd quarter valued at $562,000. Jennison Associates LLC lifted its position in shares of Kestra Medical Technologies by 15.0% during the 4th quarter. Jennison Associates LLC now owns 219,355 shares of the company's stock valued at $5,817,000 after acquiring an additional 28,573 shares during the period. TD Asset Management Inc lifted its position in shares of Kestra Medical Technologies by 17.3% during the 3rd quarter. TD Asset Management Inc now owns 92,306 shares of the company's stock valued at $2,193,000 after acquiring an additional 13,588 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Kestra Medical Technologies during the 3rd quarter valued at $48,000. Finally, Russell Investments Group Ltd. lifted its position in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock worth $41,000 after buying an additional 474 shares during the last quarter.</p>
<div class="lb-trans"><p>機構投資者最近調整了對該股票的持有情況。Mirae Asset Global Investments Co. Ltd. 在第三季度購買了價值 562,000 美元的 Kestra Medical Technologies 新股份。Jennison Associates LLC 在第四季度將其在 Kestra Medical Technologies 的持股比例提高了 15.0%。Jennison Associates LLC 現在擁有 219,355 股該公司的股票，估值為 5,817,000 美元，此前在此期間又購買了 28,573 股。TD Asset Management Inc 在第三季度將其在 Kestra Medical Technologies 的持股比例提高了 17.3%。TD Asset Management Inc 現在擁有 92,306 股該公司的股票，估值為 2,193,000 美元，此前在此期間又購買了 13,588 股。China Universal Asset Management Co. Ltd. 在第三季度購買了價值 48,000 美元的 Kestra Medical Technologies 新股份。最後，Russell Investments Group Ltd. 在第四季度將其在 Kestra Medical Technologies 的持股比例提高了 43.5%。Russell Investments Group Ltd. 現在擁有 1,563 股該公司的股票，價值 41,000 美元，此前在上個季度又購買了 474 股。</p>
</div><h2>Kestra Medical Technologies Stock Performance</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 股票表現</h2>
</div><p>Shares of NASDAQ KMTS opened at $20.55 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The stock's fifty day moving average price is $21.34 and its two-hundred day moving average price is $24.20. Kestra Medical Technologies has a one year low of $13.25 and a one year high of $30.00. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -5.19 and a beta of 0.82.</p>
<div class="lb-trans"><p>納斯達克 KMTS 的股票在星期二開盤價為 20.55 美元。該公司的債務與股本比率為 0.15，流動比率為 7.32，速動比率為 7.32。該股票的 50 日移動平均價格為 21.34 美元，200 日移動平均價格為 24.20 美元。Kestra Medical Technologies 的一年低點為 13.25 美元，一年高點為 30.00 美元。該公司的市值為 12 億美元，市盈率為-5.19，貝塔值為 0.82。</p>
</div><p>Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The firm had revenue of $24.55 million during the quarter. The company's revenue for the quarter was up 62.7% compared to the same quarter last year. On average, equities analysts forecast that Kestra Medical Technologies will post -2.34 EPS for the current year.</p>
<div class="lb-trans"><p>Kestra Medical Technologies（納斯達克股票代碼：KMTS - 獲取免費報告）最近於 3 月 17 日星期二發佈了季度財報。該公司報告季度每股收益（EPS）為（0.61）美元，低於分析師的共識預期（0.60）美元，差額為（0.01）美元。Kestra Medical Technologies 的淨利潤率為-171.87%，股本回報率為-65.49%。該公司在本季度的收入為 2455 萬美元。與去年同期相比，該公司的季度收入增長了 62.7%。分析師平均預測，Kestra Medical Technologies 在當前年度將發佈-2.34 美元的每股收益。</p>
</div><h2>About Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>關於 Kestra Medical Technologies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.</p>
<div class="lb-trans"><p>我們是一家商業階段的可穿戴醫療設備和數字醫療公司，專注於通過直觀、智能和互聯的監測和治療干預技術來改善心血管疾病患者的結果。我們開發並商業化了我們的心臟恢復系統平台，這是一個綜合且先進的系統，將監測、治療、數字健康和患者支持服務整合為一個統一的解決方案。我們心臟恢復系統平台的基石是 ASSURE WCD，這是一種下一代可穿戴心臟復律除顫器（“WCD”），用於保護面臨突發心臟驟停（“SCA”）風險的患者，這是一項重大公共衞生問題，約佔美國所有心血管死亡的 50%。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Kestra Medical Technologies</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，超過 Kestra Medical Technologies</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S01UUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=KMTS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kestra Medical Technologies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Kestra Medical Technologies 嗎？</h2>
</div><p>Before you consider Kestra Medical Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Kestra Medical Technologies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Kestra Medical Technologies 並不在名單上。</p>
</div><p>While Kestra Medical Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Kestra Medical Technologies 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Kestra Medical Technologies, Ltd.（納斯達克股票代碼：KMTS）被券商給予 “持有” 評級的平均評價